KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Net Income (2016 - 2025)

Biogen has reported Net Income over the past 17 years, most recently at -$48.9 million for Q4 2025.

  • Quarterly results put Net Income at -$48.9 million for Q4 2025, down 118.34% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 20.79% YoY), and the annual figure for FY2025 was $1.3 billion, down 20.79%.
  • Net Income for Q4 2025 was -$48.9 million at Biogen, down from $466.5 million in the prior quarter.
  • Over the last five years, Net Income for BIIB hit a ceiling of $1.1 billion in Q3 2022 and a floor of -$68.3 million in Q3 2023.
  • Median Net Income over the past 5 years was $391.0 million (2024), compared with a mean of $436.9 million.
  • Biggest five-year swings in Net Income: skyrocketed 1538.48% in 2022 and later plummeted 118.34% in 2025.
  • Biogen's Net Income stood at -$38.2 million in 2021, then skyrocketed by 1538.48% to $549.5 million in 2022, then crashed by 54.7% to $248.9 million in 2023, then rose by 7.15% to $266.7 million in 2024, then plummeted by 118.34% to -$48.9 million in 2025.
  • The last three reported values for Net Income were -$48.9 million (Q4 2025), $466.5 million (Q3 2025), and $634.8 million (Q2 2025) per Business Quant data.